Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Core Insights - The amendment to the license agreement reduces the royalty rate on Teverelix® from approximately 4% to 2%, while maintaining global rights and intellectual property control [1][2] - Teverelix® is being developed as a first-in-class product for Acute Urinary Retention relapse prevention and as a best-in-class treatment for prostate cancer patients with high cardiovascular risk, representing a potential market opportunity of around US$6 billion [1][3] License Agreement Details - The amended agreement clarifies the royalty term on a country-by-country basis and does not change the scope of the license or the underlying intellectual property [2] - Medicus retains exclusive worldwide rights to develop, manufacture, and commercialize Teverelix, including the ability to grant sublicenses, which supports flexible global partnering strategies [3][4] Economic Impact - The reduced royalty burden is expected to enhance Teverelix's attractiveness for future partnerships, particularly for late-stage development and commercialization [3] - The amendment reflects scientific progress and intellectual property expansion achieved by the Antev team, aligning the parties under a simplified economic framework [5] Development Strategy - Medicus aims to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships for late-stage development and commercialization [10] - The company is focused on assembling decision-grade clinical and regulatory data packages to support its partnering-focused model [10] Clinical Development of Teverelix - Teverelix is a long-acting injectable GnRH antagonist that suppresses sex hormone production without an initial surge, potentially reducing cardiovascular risks for patients with existing conditions [7][18] - Previous studies have shown Teverelix to be well tolerated, with significant testosterone suppression achieved in clinical trials [19][20] SkinJect™ Program - Medicus is advancing its SkinJect™ program, a proprietary dissolvable microneedle array platform for treating basal cell carcinoma, with Phase 2 data expected in early 2026 [11][24] - The company has received regulatory approvals in the UK to expand its ongoing Phase 2 clinical study for SkinJect™ [23]